Integra LifeSciences Holdings Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on events occurring at the 2026 Annual Meeting of Stockholders held on May 7, 2026. The filing details the election of directors, ratification of auditors, advisory vote on executive compensation, and approval of an amendment to the company's equity incentive plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and equity plan amendments rather than financial performance data.
Material Changes and Voting Results
- Equity Plan Amendment: Stockholders approved Amendment No. 3 to the Fifth Amended and Restated 2003 Equity Incentive Plan, increasing the number of shares available for awards by 3,550,000 shares.
- Director Elections: All eight nominees were elected to the Board of Directors. Notable "Against" votes included Barbara B. Hill (7,042,475) and Jeffrey A. Graves (3,442,844).
- Auditor Ratification: PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the 2026 fiscal year.
- Executive Compensation: The advisory vote on named executive officer compensation was approved.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. It strictly reports the outcomes of the stockholder vote.
Investor Verification Checklist
- Review the Definitive Proxy Statement (Schedule 14A) filed on April 6, 2026, for full details on the Equity Incentive Plan Amendment.
- Examine the "Against" vote percentages for directors Barbara B. Hill and Jeffrey A. Graves to understand potential shareholder concerns.
- Verify the impact of the 3,550,000 share increase on future dilution and equity compensation expenses.
- Confirm the term of the newly elected directors, which extends until the 2027 Annual Meeting.